Skip to main content
SpringerLink
Log in

Cardiac Arrhythmias

  • Reference work entry
  • First Online:
Family Medicine

  • 105 Accesses

Abstract

The electrical activation of heart muscle follows a precise and organized pathway which ensures that contraction and relaxation occur in an efficient way to support effective circulation. Arrhythmias result from an abnormal electrical activation of the heart which may lead to an abnormal rhythm, rate, or both in the heart cycle. While some arrhythmias are benign and pose no significant cardiovascular compromise, others degrade the mechanical pumping activity and lead to hemodynamic compromise and, in some cases, to collapse and/or death.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 899.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 999.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Wang PJ, Estes NA. Cardiology patient pages. Supraventricular Tachycardia Circulation. 2002;106(25):e206–8.

    PubMed  Google Scholar 

  2. Giada F, Gulizia M, Francese M, et al. Recurrent unexplained palpitations (RUP) study comparison of implantable loop recorder versus conventional diagnostic strategy. J Am Coll Cardiol. 2007;49:1951–6.

    PubMed  Google Scholar 

  3. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. Circulation. 2019;140:e125–51. https://doi.org/10.1161/CIR.0000000000000665.

    Article  PubMed  Google Scholar 

  4. Craig TJ, January L, Wann S, et al. 2014 AHA/ACC/HRS guidelines for the Management of Patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation Published on line March 28, 2014. http://circ.ahajournals.org/content/suppl/2014/10/CIR.0000000000000040.DC1.html

  5. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. Circulation. 2018;138:e210–71. https://doi.org/10.1161/CIR.0000000000000548.

    Article  PubMed  Google Scholar 

  6. Strickberger SA, Conti J, Daoud EG, et al. Patient selection for cardiac resynchronization therapy: from the council on clinical cardiology subcommittee on electrocardiography and arrhythmias and the quality of care and outcomes research interdisciplinary working group, in collaboration with the Heart Rhythm Society. Circulation. 2005;111(16):2146–50.

    PubMed  Google Scholar 

  7. Page RL, Joglar JA, Caldwell MA, et al. Evidence review committee chair‡. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. Circulation. 2016;133:e506–74.

    PubMed  Google Scholar 

  8. Jacobs I, Sunde K, Deakin CD. Et at. Part 6: defibrillation: 2010 international consensus conference on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Circulation. 2010;122(suppl2):S325–37.

    PubMed  Google Scholar 

  9. Lei M, DPhil LW, Terrar D, et al. Modernized classification of cardiac antiarrhythmic drugs. Circulation. 2018;138:1879–96.

    CAS  PubMed  Google Scholar 

  10. Mathew ST, Po SS, Thadani U. Inappropriate sinus tachycardia-symptom and heart rate reduction with Ivabradine: a pooled analysis of prospective studies. Heart Rhythm. 2018;15:240–7.

    PubMed  Google Scholar 

  11. Uddin S, Price S. Anti-arrhythmic therapy. In: Hall J, editor. Encyclopedia of intensive care medicine 2012: spring reference. Berlin/Heidelberg: Springer-Verlag; 2012. 2012-08-14 10:55:27 UTC. www.springerreferrence.com.

    Google Scholar 

  12. Micromedex. http://micromedex.com/

  13. Holgate A, Foo A. Adenosine versus intravenous calcium channel antagonists for the treatment of supraventricular tachycardia in adults. Cochrane Database Syst Rev 2012, issue 2. Art. No:CD005154. https://doi.org/10.1002/14651858.CD005154.pub3.

  14. Calkins H. Catheter ablation to maintain sinus rhythm. Circulation. 2012;125:1439–45.

    PubMed  Google Scholar 

  15. Link MS, Atkins DL, Passman RS, et al. Part 6: electrical therapies: automated external defibrillators, defibrillation, cardioversion, and pacing: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122(18 Suppl 3):S706–19. Erratum in Circulation 2011;123(6):e235

    PubMed  Google Scholar 

  16. Hallstrom AP, Ornato JP, Weisfeldt M, et al. Public-access defibrillation and survival after out-of-hospital cardiac arrest. N Engl J Med. 2004;351:637–46.

    CAS  PubMed  Google Scholar 

  17. Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation. A randomized clinical trial. JAMA. 2014;312:1988–98.

    PubMed  Google Scholar 

  18. Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long term warfarin therapy: the prevail trial. J Am Coll Cardiol. 2014;64:1–12.

    PubMed  Google Scholar 

  19. Holmes DR, Doshi SK, Kar S. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol. 2015;65:2614–23.

    PubMed  Google Scholar 

  20. Vy R, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312:1988–98.

    Google Scholar 

  21. Damiano RJ, Gaynor SL, Bailey M, et al. The long-term outcome of patients with coronary disease and atrial fibrillation undergoing the cox maze procedure. J Thorac Cardiovasc Surg. 2003;126:2016–21.

    PubMed  Google Scholar 

  22. Link MS. Clinical practice. Evaluation and initial treatment of supraventricular tachycardia. N Engl J Med. 2012;376:1438–48.

    Google Scholar 

  23. Vidaillet H, Granada JF, Chyou PH, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med. 2002;113:365–70.

    PubMed  Google Scholar 

  24. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285:2370–5.

    CAS  PubMed  Google Scholar 

  25. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham heart study. Circulation. 2003;107(23):2920–5.

    PubMed  Google Scholar 

  26. Pederson OD, Abildstrom SZ, Ottesen MM, et al. Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction. Eur Heart J. 2006;27:290–5.

    Google Scholar 

  27. Chen HS, Wen JM, Wu SN, et al. Catheter ablation for paroxysmal and persistent atrial fibrillation. Cochrane Database Syst Rev. 2012;4:CD007101.

    Google Scholar 

  28. Sherman DG, Kim SG, Boop BS, et al. Occurrence and characteristics of stroke events in the atrial fibrillation follow-up investigation of sinus rhythm management (AFFIRM) study. Arch Intern Med. 2005;165:1185–91.

    PubMed  Google Scholar 

  29. Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the rate control versus electrical cardioversion (RACE) study. J. Am Coll Cardiol. 2004;43(2):241–7.

    Google Scholar 

  30. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834–40.

    PubMed  Google Scholar 

  31. Gutierrez C, Blanchard D. Atrial fibrillation: diagnosis and treatment. Am Fam Physician. 2011;83:61–8.

    PubMed  Google Scholar 

  32. Lip GY. Implications of the CHA2DS2-VASc and HAS-BLED scores for thromboprophylaxis in atrial fibrillation. Am J Med. 2011;124:111–4.

    PubMed  Google Scholar 

  33. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. Chest. 2010;138:1093–100.

    PubMed  Google Scholar 

  34. Apostolakis S, Lane DA, Guo Y, et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk–prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012;60:861–7.

    PubMed  Google Scholar 

  35. Roldan V, Marin F, Fernandez H, et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real world” population with atrial fibrillation receiving anticoagulation therapy. Chest. 2013;143:179–84.

    PubMed  Google Scholar 

  36. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

    CAS  PubMed  Google Scholar 

  37. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in non valvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

    CAS  PubMed  Google Scholar 

  38. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.

    CAS  PubMed  Google Scholar 

  39. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. NEJM. 2013;369:2093–104.

    CAS  PubMed  Google Scholar 

  40. Xian Y, Xu H, O'Brien EC, et al. Clinical effectiveness of direct Oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study. JAMA Neurol. 2019;76(10):1192–202.

    PubMed  PubMed Central  Google Scholar 

  41. Steinberg BA, Piccini JP. Anticoagulation in atrial fibrillation. BMJ. 2014;348:g2116.

    PubMed  PubMed Central  Google Scholar 

  42. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014;383:955–62.

    CAS  PubMed  Google Scholar 

  43. Weitz JI, Connolly SJ, Patel I, et al. Randomized, parallel-group, multicenter, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633–41.

    CAS  PubMed  Google Scholar 

  44. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007:CD006186.

    Google Scholar 

  45. Perez-Gomez F, Alegria E, Berjon J, et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol. 2004; 44(8):1557–66.

    Google Scholar 

  46. Connolly S, Pogue J, Hart R, et al. ACTIVE writing group of the ACTIVE investigators. clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE W): a randomized controlled trial. Lancet. 2006;367:1903–12.

    CAS  PubMed  Google Scholar 

  47. Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran reversal- full cohort analysis. N Engl J Med. 2017;377:431–41.

    CAS  PubMed  Google Scholar 

  48. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alpha for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413–24.

    CAS  PubMed  Google Scholar 

  49. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373:823–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Bacon D, Philips B. Ventricular arrhythmias. In: Hall J., Vincent J. (Ed.) Encyclopedia of intensive medicine spring reference. Springer-Veriag Berlin/Heidelberg 2012. 2012-08-14 10:55:00 UTC. www.springerreference.com.

  51. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New Engl J Med. 2002;346:877–33.

    PubMed  Google Scholar 

  52. Huang Y, He Q, Yang LJ, et al. Cardiopulmonary resuscitation (CPR) plus delayed defibrillation versus immediate defibrillation for out-of-hospital cardiac arrest. Cochrane Database Syst Rev 2014, Issue 9. Art. No.: CD 009803. https://doi.org/10.1002/14651858.CD009803.pub2

  53. Neira V, Enriquez A, Simpson C, et al. Update on long QT syndrome. J Cardiovasc Electrophysiol. 2019;30:3068–78.

    PubMed  Google Scholar 

  54. Straus SM, Sturkenboom MC, Bleumink GS, et al. Non-cardiac QTc-prolonging drugs and the risk of cardiac sudden death. Eur Heart J. 2005;26:2007–12.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Family Medicine and Public Health, UCSD School of Medicine, University of California, San Diego, San Diego, CA, USA

    Cecilia Gutierrez & Esmat Hatamy

Authors
  1. Cecilia Gutierrez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Esmat Hatamy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cecilia Gutierrez .

Editor information

Editors and Affiliations

  1. Department of Family Medicine, University of Nebraska Medical Center, Omaha, NE, USA

    Paul M. Paulman

  2. Department of Family and Community Medicine, Eastern Virginia Medical School, Norfolk, VA, USA

    Robert B. Taylor

  3. Department of Family Medicine, University of Nebraska Medical Center, Omaha, NE, USA

    Audrey A. Paulman

  4. Department of Family Medicine, Creighton University School of Medicine, Omaha, NE, USA

    Laeth S. Nasir

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Gutierrez, C., Hatamy, E. (2022). Cardiac Arrhythmias. In: Paulman, P.M., Taylor, R.B., Paulman, A.A., Nasir, L.S. (eds) Family Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-54441-6_84

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-54441-6_84

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-54440-9

  • Online ISBN: 978-3-030-54441-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation